Apothecary Pharma, LLC
Has Apothecary Pharma, LLC received an FDA warning letter? Yes. FDA issued a warning letter dated December 1, 2025 concerning products containing tirzepatide and semaglutide.
Letter facts
- Letter date
- December 1, 2025 (2025-12-01)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Compounding Pharmacy
- Products named
- Tirzepatide Injection 10 mg/mLSemaglutide Injection 2.5 mg/mLcompounded sterile drug products
- Violation categories
- Unapproved new drugMisbrandingCompounding outside 503A/503BCGMP / insanitary conditions
Understanding these violation categories
Unapproved new drug
FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
Compounding outside 503A/503B
FDA says this pharmacy's compounded products did not meet the conditions that let pharmacies compound drugs without FDA approval. A warning letter is FDA's notice of what it believes are significant violations; the company can respond.
CGMP / insanitary conditions
FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.
Factual Violation Summary
FDA says the firm compounded sterile drugs under insanitary conditions with poor aseptic practices and airflow, and cited CGMP failures in quality control, procedures, clothing, cleaning, and batch records; missing label ingredients and directions; inadequate adverse event reporting; and unapproved and misbranded drugs.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- Failure to meet section 503B conditions
- Labeling deficiencies
- Inadequate adverse event reporting
- Adulterated drug products (insanitary conditions)
- CGMP violations
- Unapproved new drug products
- Misbranded drug products
More letters about Semaglutide
Recent FDA warning letters concerning Semaglutide:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Similar violations (Unapproved new drug)
Recent warning letters with related regulatory findings:
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.